Dicle Medical Journal
pISSN 1300-2945    eISSN 1308-9889
Archival Issues
Volume 38, 2011
Volume 37, 2010
Volume 36, 2009
Volume 35, 2008
Volume 34, 2007
Volume 33, 2006
Volume 32, 2005
Volume 31, 2004
Volume 30, 2003
Search
Manuscript Submission
Newsletter
News
Language
Language:
 
Copyright Transfer Agreement
Indexation
 » 
Journal Abstract
 
Effect of bismuth addition to the triple therapy of Helicobacter pylori eradication
Ayhan Hilmi Çekin 1, Nur Turgut Tükel 2, Yeşim Çekin 3, Cem Sezer 4, Ezel Taşdemir 2
1 - Antalya Eğitim ve Araştırma Hastanesi, Gastroenteroloji Kliniği, Antalya, Türkiye
2 - Antalya Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Antalya, Türkiye
3 - Antalya Eğitim ve Araştırma Hastanesi, Mikrobiyoloji Kliniği, Antalya, Türkiye
4 - Antalya Eğitim ve Araştırma Hastanesi, Patoloji Kliniği, Antalya, Türkiye
Dicle Med J 2012; 39(1):54-57
ICID: 987021
Article type: Original article
IC™ Value: 3.00
Abstract provided by Publisher
 
Objective: Success rates of amoxicillin, clarithromycin,
and proton-pump inhibitor therapy in the Helicobacter pylori
(Hp) eradication have been decreasing. The aim of
this study was to investigate the impact of bismuth subcitrate
addition to triple therapy.
Materials and methods: 148 patients diagnosed Hp infection
with both histology and Hp stool antigen (HpSA)
tests were examined retrospectively. The patients were
divided into 3 groups according to the eradication therapy.
The first group received triple therapy with claritromycine
2x 500 mg, amoxicilline 2x1 g and PPI 2x1 for 14 days
(n=40). The second group had bismuth subcitrate 4x120
mg with triple therapy for 14 days (n=73). The third group
received 14 days pretreatment with bismuth subcitrate
4x1 together with PPI 2x1 then had triple therapy for 14
days (n=35). (14)C urea breath and HpSA tests were
used to detect posttreatment H.pylori status.
Results: There were no statistical difference between the
groups in terms of gender and age (p > 0.05). In group
one 12 patients, in group two 20 patients and in group
three 10 patients were identified as Hp positive after treatment.
Eradication rates were 70% for group one, 72.6%
for group two and 71.4% for group three respectively.
There was no statistical difference between the groups in
terms of eradication rates of treatment (p > 0.05).
Conclusions: The addition of bismuth to conventional
triple therapy did not affect treatment success rates.

ICID 987021
 
FULL TEXT 478 KB
 
FULL TEXT


Related articles
  • in IndexCopernicus™
         proton-pump inhibitor [0 related records]
         Amoxicillin [32 related records]
         clarithromycin [27 related records]
         bismuth subcitrate [0 related records]
         Helicobacter pylori [575 related records]


  •  
     » 
    Comments
     
      
    Comments: 0
    Published remarks are private opinions of the users.
    Editorial office of the service do not take responsibility for them.

    Copyright © Dicle Medical Journal   2017
    Page created by Index Copernicus Ltd. All Rights reserved.